Clinical study of treating acute leukemia and multiple myeloma with a novel vaccine

Objective: To investigate the efficacy and side effects of treating acute leukemia (AL) and multiple myeloma (MM) with a novel vaccine of active immunization. Methods: Thirty-seven patients with AL and 7 with MM received the active immunotherapy of the vaccine. The vaccine was produced by tumor cells of AL and cytokine was manufactured by genetic engineering. Results: Of the 37 cases of AL, no remission of chemotherapy and intolerance with chemotherapy appeared in 29 cases. Five cases had complete remission by the vaccine therapy (17.3%), 8 had partial remission (20.7%) and 5 had minute remission (13.8%), with the efficiency rate being 51.8%. Another 8 cases receiving active immunity therapy of novel vaccine relapsed until 8-13 months later. Of the 7 cases of MM, 1 case had complete remission and 5 cases had partial remission. No side effects were observed in all the patients receiving vaccine injection. Conclusion: The results showed that the active immunotherapy with the novel vaccine has an apparent effect on some patients with AL and MM. In addition, the vaccine therapy is economical and has no side effects.